Krajnc, Nik
Frank, Florian
Macher, Stefan
Michl, Martin
Müller, Nina
Maier, Sarah
Zaic, Sina
Wöber, Christian
Pemp, Berthold
Broessner, Gregor
Bsteh, Gabriel
Article History
Received: 24 March 2024
Accepted: 28 May 2024
First Online: 4 June 2024
Declarations
:
: The study was approved by the ethics committee of the Medical University Vienna (ethical approval number: 2216/2020). Written informed consent was obtained from all patients.
: Not applicable.
: Nik Krajnc: has participated in meetings sponsored by, received speaker honoraria or travel funding from Alexion, BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Florian Frank: nothing to disclose.Stefan Macher: declares no conflict of interest relevant to this study.Martin Michl: declares no conflict of interest relevant to this study.Nina Müller: declares no conflict of interest relevant to this study.Sarah Maier: declares no conflict of interest relevant to this study.Sina Zaic: declares no conflict of interest relevant to this study.Berthold Pemp: has received honoraria for speaking from Novartis.Christian Wöber: has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grünenthal, Hermes, Lundbeck, Novartis, Pfizer, Ratiopharm/Teva, and Stada.Gregor Broessner: has received unrestricted grants, honoraria, personal fees, travel grants from Allergan, AMGEN, Menarini, Pfizer, Linde AG, Astra Zeneca, St. Jude Medical, Reckitt Benkiser, Novartis, TEVA, Fresenius, Janssen Cilag, Lilly, Österreichische Gesellschaft für Neurologie (ÖGN), European Headache Foundation (EHF), Österreichische Kopfschmerzgesellschaft (ÖKSG), Österreichische Akademie der Wissenschaften (ÖAW) and European FP7 Framework Programme.Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis.